Literature DB >> 20421433

Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant Staphylococcus aureus in a pediatric population.

Jacob S Hogue1, Patricia Buttke, LoRanee E Braun, Mary P Fairchok.   

Abstract

We investigated the proportion of methicillin-resistant Staphylococcus aureus (MRSA) isolates from pediatric patients demonstrating mupirocin resistance related to mupirocin use at our institution. No mupirocin resistance was found in 98% of isolates, whereas mupirocin prescriptions increased by 110%. Resistance rates remained low despite the increasing use of mupirocin.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20421433      PMCID： PMC2897475          DOI： 10.1128/JCM.02118-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples.

Authors:  Fernando Chaves; Jesus García-Martínez; Sonia de Miguel; Joaquín R Otero
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions.

Authors:  Elaine S Walker; Foster Levy; Mahmoud Shorman; Gerard David; Jehad Abdalla; Felix A Sarubbi
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

3.  The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital.

Authors:  J E Vasquez; E S Walker; B W Franzus; B K Overbay; D R Reagan; F A Sarubbi
Journal:  Infect Control Hosp Epidemiol       Date:  2000-07       Impact factor: 3.254

4.  Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment.

Authors:  M A Miller; A Dascal; J Portnoy; J Mendelson
Journal:  Infect Control Hosp Epidemiol       Date:  1996-12       Impact factor: 3.254

5.  Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance.

Authors:  A Upton; S Lang; H Heffernan
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

6.  Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital.

Authors:  Hee-Jeong Yun; Sang Won Lee; Gyu Man Yoon; Su Yeon Kim; Sooyoung Choi; Yeong Seon Lee; Eung-Chil Choi; Sunghoon Kim
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

7.  Mupirocin resistance in clinical isolates of Staphylococcus aureus.

Authors:  Paula G Jones; Terri Sura; Michael Harris; Anne Strother
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

8.  Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001.

Authors:  Michael Kresken; Dieter Hafner; Franz-Josef Schmitz; Thomas A Wichelhaus
Journal:  Int J Antimicrob Agents       Date:  2004-06       Impact factor: 5.283

9.  Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.

Authors:  Andrew E Simor; Tammy L Stuart; Lisa Louie; Christine Watt; Marianne Ofner-Agostini; Denise Gravel; Michael Mulvey; Mark Loeb; Allison McGeer; Elizabeth Bryce; Anne Matlow
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

10.  The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals.

Authors:  F J Schmitz; E Lindenlauf; B Hofmann; A C Fluit; J Verhoef; H P Heinz; M E Jones
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790
View more
  15 in total

1.  Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children.

Authors:  J Chase McNeil; Kristina G Hulten; Sheldon L Kaplan; Edward O Mason
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Molecular characterization of high-level mupirocin resistance in Staphylococcus pseudintermedius.

Authors:  Krešimir Matanovic; Eduardo Pérez-Roth; Selma Pintarić; Branka Šeol Martinec
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

3.  Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Allison R McMullen; William Lainhart; Meghan A Wallace; Angela Shupe; Carey-Ann D Burnham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-24       Impact factor: 3.267

4.  High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population.

Authors:  Nina K Antonov; Maria C Garzon; Kimberly D Morel; Susan Whittier; Paul J Planet; Christine T Lauren
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

5.  Rapid MRSA PCR on respiratory specimens from ventilated patients with suspected pneumonia: a tool to facilitate antimicrobial stewardship.

Authors:  S E Trevino; M A Pence; J Marschall; M H Kollef; H M Babcock; C-A D Burnham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-21       Impact factor: 3.267

6.  Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections.

Authors:  Stephanie A Fritz; Patrick G Hogan; Bernard C Camins; Ali J Ainsworth; Carol Patrick; Madeline S Martin; Melissa J Krauss; Marcela Rodriguez; Carey-Ann D Burnham
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

7.  Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial.

Authors:  Stephanie A Fritz; Bernard C Camins; Kimberly A Eisenstein; Joseph M Fritz; Emma K Epplin; Carey-Ann Burnham; Jonathan Dukes; Gregory A Storch
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09       Impact factor: 3.254

8.  A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein.

Authors:  Vivek Daniel Paul; Sanjeev Saravanan Rajagopalan; Sudarson Sundarrajan; Shilpa E George; Jiya Y Asrani; Renjith Pillai; Ravisha Chikkamadaiah; Murali Durgaiah; Bharathi Sriram; Sriram Padmanabhan
Journal:  BMC Microbiol       Date:  2011-10-11       Impact factor: 3.605

9.  Six-Year Retrospective Review of Hospital Data on Antimicrobial Resistance Profile of Staphylococcus aureus Isolated from Skin Infections from a Single Institution in Greece.

Authors:  Christina Stefanaki; Alexandra Ieronymaki; Theoni Matoula; Chrysseis Caroni; Evaggelia Polythodoraki; Stella-Eugenia Chryssou; George Kontochristopoulos; Christina Antoniou
Journal:  Antibiotics (Basel)       Date:  2017-12-20

10.  Prevalence of Mupirocin Resistant Staphylococcus aureus Isolates Among Patients Admitted to a Tertiary Care Hospital.

Authors:  Parul Chaturvedi; Amit Kumar Singh; Amit Kumar Singh; Snehanshu Shukla; Loveleena Agarwal
Journal:  N Am J Med Sci       Date:  2014-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.